Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluate the Possible Efficacy and Safety of Empagliflozin in Patient With Ulcerative Colitis
Sponsor: Tanta University
Summary
•This study will be a randomized, controlled, parallel study. .To demonstrate the efficacy of empagliflozin and clinical improvement in patients of mild to moderate UC using the Montreal classification of severity of ulcerative colitis.
Official title: Clinical Study to Evaluate the Possible Efficacy and Safety of Empagliflozin in Patients With Ulcerative Colitis
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2023-01-01
Completion Date
2026-12-01
Last Updated
2025-07-16
Healthy Volunteers
No
Conditions
Interventions
Empagliflozin
Patients will receive empagliflozin (0.4 - 0.5mg/kg/day) orally (maximum dose 25mg per day)and conventional treatment (corticosteroids +immune suppressive + aminosalicylic acid)for 4 months.
conventional treatment
conventional treatment (corticosteroids +immune suppressive + aminosalicylic acid)for 4 months
Locations (1)
Gastroenterology and Endoscopy Unit, Internal Medicine Department, Tanta University Hospital.
Tanta, Egypt